Engimmune Therapeutics AG

Our goal is to develop best-in-class T cell engagers with our AI-guided technology platforms. We have already engineered TCR leads targeting a widely expressed tumor target with remarkable levels of specificity, and have commenced the development of TCRs against additional targets. From a business perspective, we aim to establish strategic partnerships with large biopharmaceutical companies for the licensing of internal assets and co-development of external assets.